Division of Nephrology and Hypertension, Department of Medicine, Northwestern University/Feinberg School of Medicine, Chicago, Illinois, USA; Charité University Medicine Berlin, Berlin, Germany.
Division of Nephrology and Hypertension, Department of Medicine, Northwestern University/Feinberg School of Medicine, Chicago, Illinois, USA.
Kidney Int. 2021 Apr;99(4):900-913. doi: 10.1016/j.kint.2020.11.012. Epub 2020 Dec 11.
Aminopeptidase A is one of the most potent enzymes within the renin-angiotensin system in terms of angiotensin II degradation. Here, we examined whether there is a kidney phenotype and any compensatory changes in other renin angiotensin system enzymes involved in the metabolism of angiotensin II associated with aminopeptidase A deficiency. Kidneys harvested from aminopeptidase A knockout mice were examined by light and electron microscopy, immunohistochemistry and immunofluorescence. Kidney angiotensin II levels and the ability of renin angiotensin system enzymes in the glomerulus to degrade angiotensin II ex vivo, their activities, protein and mRNA levels in kidney lysates were evaluated. Knockout mice had increased blood pressure and mild glomerular mesangial expansion without significant albuminuria. By electron microscopy, knockout mice exhibited a mild increase of the mesangial matrix, moderate thickening of the glomerular basement membrane but a striking appearance of knob-like structures. These knobs were seen in both male and female mice and persisted after the treatment of hypertension. In isolated glomeruli from knockout mice, the level of angiotensin II was more than three-fold higher as compared to wild type control mice. In kidney lysates from knockout mice angiotensin converting enzyme activity, protein and mRNA levels were markedly decreased possibly as a compensatory mechanism to reduce angiotensin II formation. Thus, our findings support a role for aminopeptidase A in the maintenance of glomerular structure and intra-kidney homeostasis of angiotensin peptides.
氨基肽酶 A 是肾素-血管紧张素系统中降解血管紧张素 II 最有效的酶之一。在这里,我们研究了与氨基肽酶 A 缺乏相关的血管紧张素 II 代谢中涉及的肾素-血管紧张素系统其他酶是否存在肾脏表型和任何代偿性变化。通过光镜和电子显微镜、免疫组织化学和免疫荧光检查从氨基肽酶 A 敲除小鼠中取出的肾脏。评估了肾脏中的血管紧张素 II 水平以及肾小球中肾素-血管紧张素系统酶体外降解血管紧张素 II 的能力、它们的活性、肾脏裂解物中的蛋白和 mRNA 水平。敲除小鼠的血压升高,肾小球系膜扩张轻度,但白蛋白尿不明显。通过电子显微镜检查,敲除小鼠表现出系膜基质轻度增加,肾小球基底膜中度增厚,但出现明显的小结节样结构。这些小结节样结构在雄性和雌性小鼠中均可见,并且在高血压治疗后仍然存在。与野生型对照小鼠相比,从敲除小鼠的分离肾小球中血管紧张素 II 的水平高出三倍以上。在敲除小鼠的肾脏裂解物中,血管紧张素转换酶活性、蛋白和 mRNA 水平明显降低,这可能是一种代偿机制,以减少血管紧张素 II 的形成。因此,我们的研究结果支持氨基肽酶 A 在维持肾小球结构和肾脏内血管紧张素肽内稳态方面的作用。